These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22797189)

  • 1. Rituximab in membranous nephropathy: is it a first-line treatment?
    Appel GB
    J Am Soc Nephrol; 2012 Aug; 23(8):1280-2. PubMed ID: 22797189
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy.
    Zhu B; Huang J
    Pediatr Nephrol; 2011 Apr; 26(4):637-8. PubMed ID: 21046167
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasmapheresis combined with rituximab for refractory idiopathic membranous nephropathy.
    Wen M; Küchle C; Sarkar O; Renders L; Heemann U; Schmaderer C
    Int Urol Nephrol; 2014 Apr; 46(4):847-8. PubMed ID: 24585365
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P; Remuzzi G; Ruggenenti P
    Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for membranous nephropathy and immune disease: less might be enough.
    Ruggenenti P; Cravedi P; Remuzzi G
    Nat Clin Pract Nephrol; 2009 Feb; 5(2):76-7. PubMed ID: 19048001
    [No Abstract]   [Full Text] [Related]  

  • 6. [Membranous nephropathy secondary to rheumatoid arthritis occurring during anti-TNFalpha therapy and responsive to second-line treatment with rituximab].
    Giordano A; Cencioni L; Salvo DP; Berrettini M
    G Ital Nefrol; 2011; 28(2):214-8. PubMed ID: 21488037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
    Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab treatment of idiopathic membranous nephropathy.
    Fervenza FC; Cosio FG; Erickson SB; Specks U; Herzenberg AM; Dillon JJ; Leung N; Cohen IM; Wochos DN; Bergstralh E; Hladunewich M; Cattran DC
    Kidney Int; 2008 Jan; 73(1):117-25. PubMed ID: 17943078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
    Cravedi P; Sghirlanzoni MC; Marasà M; Salerno A; Remuzzi G; Ruggenenti P
    Am J Nephrol; 2011; 33(5):461-8. PubMed ID: 21508634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in idiopathic membranous nephropathy.
    Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
    J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy.
    Busch M; Rüster C; Schinköthe C; Gerth J; Wolf G
    Clin Nephrol; 2013 Aug; 80(2):105-13. PubMed ID: 23587125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab.
    Dedinská I; Svetlík D; Adamicova K; Machalekova K; Makovicky P; Jezikova A; Laca L; Miklusica J; Galajda P; Mokan M
    Iran J Kidney Dis; 2016 Sep; 10(5):332-335. PubMed ID: 27721233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.
    Irazabal MV; Eirin A; Lieske J; Beck LH; Sethi S; Borland TM; Dillon JJ; Nachman PH; Nasr SH; Cornell LD; Leung N; Cattran DC; Fervenza FC
    Nephrol Dial Transplant; 2013 Jan; 28(1):137-46. PubMed ID: 22987142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in membranous nephropathy.
    Ring T
    Kidney Int; 2008 Aug; 74(3):391-2; author reply 392. PubMed ID: 18626501
    [No Abstract]   [Full Text] [Related]  

  • 15. The Efficacy of Rituximab in the Treatment of Membranous Nephropathy.
    Maharjan R; Wang JW; Shrestha IK
    J Nepal Health Res Counc; 2021 Jan; 18(4):580-587. PubMed ID: 33510493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic tests and treatment options in glomerular disease: 2014 update.
    Hogan J; Mohan P; Appel GB
    Am J Kidney Dis; 2014 Apr; 63(4):656-66. PubMed ID: 24239051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse of membranous glomerulopathy after kidney transplantation: sustained remittance induced by rituximab.
    Weclawiak H; Ribes D; Guilbeau-Frugier C; Touchard G; Kamar N; Mehrenberger M; Modesto A; Rostaing L
    Clin Nephrol; 2008 May; 69(5):373-6. PubMed ID: 18538101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful therapeutic use of rituximab in refractory membranous glomerulonephritis.
    Cobo M; Hernández D; Rodriguez C; Pérez-Tamajón L
    Clin Nephrol; 2006 Jul; 66(1):54-7. PubMed ID: 16878436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?
    Esposito P; Grosjean F; Mangione F; Domenech MV; Rampino T
    Clin Exp Nephrol; 2018 Feb; 22(1):208-209. PubMed ID: 28660444
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report.
    Vischini G; Cudillo L; Ferrannini M; Di Daniele N; Cerretti R; Arcese W
    J Nephrol; 2009; 22(1):160-3. PubMed ID: 19229832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.